NCT06460961View on ClinicalTrials.gov

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

PHASE1RecruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

July 14, 2024

Primary Completion Date

July 13, 2029

Study Completion Date

July 13, 2029

Conditions
Neoplasm Metastasis
Interventions
BIOLOGICAL

MK-6837

IV Infusion

BIOLOGICAL

Pembrolizumab

IV Infusion

DRUG

Rescue Medications

Antihistamine, H2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) administered per product label prior to MK-6837.

Trial Locations (7)

2145

RECRUITING

Westmead Hospital ( Site 1002), Westmead

3004

RECRUITING

The Alfred Hospital ( Site 1001), Melbourne

78229

RECRUITING

South Texas Accelerated Research Therapeutics (START) ( Site 4003), San Antonio

97213

RECRUITING

Providence Portland Medical Center ( Site 4002), Portland

5265601

RECRUITING

Sheba Medical Center-ONCOLOGY ( Site 3001), Ramat Gan

07960

RECRUITING

Atlantic Health System Morristown Medical Center ( Site 4001), Morristown

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre ( Site 2001), Toronto

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY